- Home
- FORA vs PSTV Comparison
FORA vs PSTV Comparison
Compare FORA & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- PSTV
- Stock Information
- Founded
- FORA 2014
- PSTV 1996
- Country
- FORA United States
- PSTV United States
- Employees
- FORA N/A
- PSTV N/A
- Industry
- FORA Computer Software: Prepackaged Software
- PSTV Medical/Dental Instruments
- Sector
- FORA Technology
- PSTV Health Care
- Exchange
- FORA Nasdaq
- PSTV Nasdaq
- Market Cap
- FORA 69.4M
- PSTV 61.1M
- IPO Year
- FORA N/A
- PSTV N/A
- Fundamental
- Price
- FORA $2.11
- PSTV $0.49
- Analyst Decision
- FORA
- PSTV Strong Buy
- Analyst Count
- FORA 0
- PSTV 4
- Target Price
- FORA N/A
- PSTV $7.75
- AVG Volume (30 Days)
- FORA 39.0K
- PSTV 5.9M
- Earning Date
- FORA 11-14-2025
- PSTV 10-30-2025
- Dividend Yield
- FORA N/A
- PSTV N/A
- EPS Growth
- FORA N/A
- PSTV N/A
- EPS
- FORA N/A
- PSTV N/A
- Revenue
- FORA $28,106,911.00
- PSTV $5,258,000.00
- Revenue This Year
- FORA $47.82
- PSTV $9.91
- Revenue Next Year
- FORA $10.11
- PSTV $1.06
- P/E Ratio
- FORA N/A
- PSTV N/A
- Revenue Growth
- FORA 37.47
- PSTV N/A
- 52 Week Low
- FORA $1.64
- PSTV $0.16
- 52 Week High
- FORA $4.03
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- FORA 44.32
- PSTV 40.74
- Support Level
- FORA $2.05
- PSTV $0.46
- Resistance Level
- FORA $2.30
- PSTV $0.56
- Average True Range (ATR)
- FORA 0.10
- PSTV 0.05
- MACD
- FORA -0.01
- PSTV -0.00
- Stochastic Oscillator
- FORA 28.78
- PSTV 23.17
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).